Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$76.98M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1275.28%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$196.9M
Q3 2024
Cash
Q3 2024
P/E
-2.722
Nov 29, 2024 EST
Free Cash Flow
-$63.76M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020
Revenue $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020
Revenue $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020
Selling, General & Admin $21.08M $8.708M $2.466M $1.298M
YoY Change 142.06% 253.12% 89.98%
% of Gross Profit
Research & Development $46.02M $23.95M $13.72M $1.870M
YoY Change 92.18% 74.58% 633.58%
% of Gross Profit
Depreciation & Amortization $536.0K $400.0K $37.00K $13.00K
YoY Change 34.0% 981.08% 184.62%
% of Gross Profit
Operating Expenses $67.10M $32.66M $16.18M $3.168M
YoY Change 105.48% 101.79% 410.86%
Operating Profit -$67.10M -$32.66M -$16.18M
YoY Change 105.48% 101.79%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020
Interest Expense $0.00 -$2.099M
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $6.715M $1.490M -$159.0K -$39.00K
YoY Change 350.67% -1037.11% 307.69%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020
Pretax Income -$60.39M -$31.17M -$16.24M -$5.306M
YoY Change 93.76% 91.88% 206.13%
Income Tax
% Of Pretax Income
Net Earnings -$60.39M -$31.17M -$16.24M -$5.306M
YoY Change 93.76% 91.88% 206.13%
Net Earnings / Revenue
Basic Earnings Per Share -$2.74 -$7.56 -$9.32
Diluted Earnings Per Share -$2.74 -$7.56 -$510.2K -$166.7K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020
Cash & Short-Term Investments $127.5M $127.8M $99.60M $1.583M
YoY Change -0.23% 28.26% 6192.04%
Cash & Equivalents $36.02M $29.52M $99.60M $1.583M
Short-Term Investments $91.44M $98.23M
Other Short-Term Assets $2.234M $4.344M $805.0K $136.0K
YoY Change -48.57% 439.63% 491.91%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $129.7M $132.1M $100.4M $1.719M
YoY Change -1.82% 31.56% 5741.07%
Property, Plant & Equipment $7.908M $6.862M $5.791M $59.00K
YoY Change 15.24% 18.49% 9715.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $41.88M
YoY Change -100.0%
Other Assets $665.0K $388.0K $388.0K $407.0K
YoY Change 71.39% 0.0% -4.67%
Total Long-Term Assets $8.573M $49.13M $6.179M $466.0K
YoY Change -82.55% 695.13% 1225.97%
Total Assets $138.3M $181.2M $106.6M $2.185M
YoY Change
Accounts Payable $5.048M $904.0K $964.0K $136.0K
YoY Change 458.41% -6.22% 608.82%
Accrued Expenses $8.255M $5.543M $1.884M $419.0K
YoY Change 48.93% 194.21% 349.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $58.00K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.30M $6.516M $2.914M $613.0K
YoY Change 104.16% 123.61% 375.37%
Long-Term Debt $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.767M $4.235M $4.964M $318.0K
YoY Change -11.05% -14.69% 1461.01%
Total Long-Term Liabilities $3.767M $4.235M $4.964M $318.0K
YoY Change -11.05% -14.69% 1461.01%
Total Liabilities $17.07M $10.75M $7.878M $931.0K
YoY Change 58.78% 36.47% 746.19%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020
Basic Shares Outstanding 22.08M 4.122M 1.743M
Diluted Shares Outstanding 22.08M 4.122M 1.743M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $209.55 Million

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2022-11-15. The firm uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Industry: Pharmaceutical Preparations Peers: Aldeyra Therapeutics, Inc. Allakos Inc. Anika Therapeutics, Inc. Arbutus Biopharma Corp Tango Therapeutics, Inc. Compass Therapeutics, Inc. Nurix Therapeutics, Inc. Poseida Therapeutics, Inc. SANGAMO THERAPEUTICS, INC